43 Recruiting Trials

Clinical Trials
for Breast Cancer in Nebraska

43 clinical trials for Breast Cancer are currently recruiting participants at study sites in Nebraska. Study-related care is provided at no cost.

43
Recruiting trials
54
Study sites
9
Cities
30
Industry-sponsored
13
Phase 2
19
Phase 3

Breast Cancer clinical trials in Nebraska: what to expect

Breast cancer trials are sorted first by subtype, because the treatments differ: hormone-receptor-positive, HER2-positive (including the newer HER2-low group) and triple-negative disease each have their own studies. Most recruiting trials test a new drug or combination, including targeted pills, antibody-drug conjugates and immunotherapy, either for metastatic cancer or before and after surgery for early-stage disease. Others study less surgery or radiation, ways to reduce recurrence, and screening for people at higher risk.

In Nebraska, recruiting breast cancer studies are concentrated in Omaha, Lincoln, Grand Island and Kearney, with sites in 5 other cities. 30 of the 43 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who breast cancer trials usually look for

Listings name the subtype, the stage (early or metastatic) and how many treatments you may already have had. Early-stage trials often enroll between diagnosis and surgery, or in the months after surgery; metastatic trials usually enroll when a treatment has stopped working. Some specify menopausal status or a particular mutation (BRCA, PIK3CA, ESR1), which the site can test for. Nearly all require that you are well enough for daily activity and that recent blood work is adequate.

Your receptor status is on your pathology report; the site will confirm it from that report, so you do not need to know it by heart to ask.

What taking part involves

Screening reviews your pathology and scans and adds blood work, sometimes a biopsy. Treatment then runs in cycles, with infusions every two to three weeks or daily pills, and scans every two to three months to check the response. Early-stage trials follow you for years after treatment ends, usually with a visit or call every few months. Study drugs and study-specific tests are free; care you would receive anyway is billed to insurance as usual. Placebo, when used, is added to standard treatment.

Questions worth asking the study team

How the study treatment compares with what your oncologist would otherwise recommend; whether the trial is randomized and what the other arm receives; what happens if the cancer grows or returns; and how visits fit around work and family. Many trials now allow some visits at a local clinic.

Showing 20 of 43 recruiting Breast Cancer trials in Nebraska

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
PHASE3 Goodyear, Arizona +4 sites NCT06790693
This trial is looking for adults with a specific type of advanced breast cancer to test a new treatment combo. Participants will receive either the new treatment or a placebo along with standard care.
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
PHASE3 Omaha, Nebraska +4 sites NCT07205822
This trial is looking for adults with a specific type of advanced breast cancer. Participants will receive the treatment Dato-DXd and will need to provide a tumor sample and meet certain health requirements.
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3 Daphne, Alabama +4 sites NCT06492616
This trial is looking for women and men with early breast cancer that has a high risk of coming back. Participants will compare the effects of elacestrant with standard treatment after being on another therapy for a while.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
PHASE3 Phoenix, Arizona +4 sites NCT06072612
This trial is looking for adults with advanced or locally recurrent breast cancer who have run out of treatment options. Participants will receive treatment with the Bria-IMT regimen and a checkpoint inhibitor to see how well it works compared to other standard treatments.
Recruiting
E-Mindfulness Approaches for Living After Breast Cancer
PHASE3 Phoenix, Arizona +4 sites NCT06748222
This trial is looking for younger women who have survived breast cancer and are experiencing depression. Participants will try two different mindfulness programs, one led by an instructor via Zoom and the other through a mobile app.
Recruiting
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
PHASE2 Long Beach, California +4 sites NCT07102381
This trial is looking for people with early-stage HER2-positive breast cancer to see if zanidatamab combined with chemotherapy is safe and effective. Participants will need to undergo surgery after the treatment.
Recruiting
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
PHASE1 Omaha, Nebraska +4 sites NCT06515470
This trial is looking for women with advanced breast cancer who have hormone receptor positive (HR+) and HER2 negative status. Participants will take the study drug BTX-9341 alone or with another medication called fulvestrant.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3 Birmingham, Alabama +4 sites NCT07492641
This trial is looking for people with advanced breast cancer who have not been treated for it before. Participants will receive either BGB-43395 with letrozole or a different treatment option with letrozole.
Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3 Birmingham, Alabama +4 sites NCT04852887
This trial is looking for women with early-stage hormone-sensitive breast cancer who are interested in taking part in a study on surgery and hormone therapy without radiation. Participants will need to meet specific health criteria to join.
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3 Birmingham, Alabama +4 sites NCT05633654
This trial is looking for adults with triple negative breast cancer that remains after surgery and treatment. Participants will receive an experimental treatment combining two medications after recovery from surgery.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3 Birmingham, Alabama +4 sites NCT05812807
This trial is looking for people with early-stage triple-negative breast cancer who had no cancer left after previous treatments. Participants will either continue receiving pembrolizumab or just be monitored after surgery to see which approach works better to prevent cancer from coming back.
Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05929768
This trial is looking for women with early-stage triple negative breast cancer. Participants will receive a shorter treatment plan involving chemotherapy and immunotherapy without a certain type of drug called anthracyclines.
Recruiting
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
PHASE1 Duarte, California +4 sites NCT03424005
This trial is looking for people with advanced breast cancer to test different treatment combinations. Participants will receive treatment and be monitored for their response to it over time.
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
PHASE2 Phoenix, Arizona +4 sites NCT07007559
This trial is looking for women with advanced HER2-positive breast cancer who have received previous treatment. Participants will take part in a study to see how well the drug evorpacept works when combined with trastuzumab and chemotherapy.
Recruiting

Where the Breast Cancer studies are in Nebraska

  • University of Nebraska Medical Center, Omaha14 trials
  • Nebraska Cancer Specialists, Omaha11 trials
  • CHI Health Good Samaritan, Kearney8 trials
  • Alegent Health Bergan Mercy Medical Center, Omaha6 trials
  • Alegent Health Immanuel Medical Center, Omaha6 trials
  • Alegent Health Lakeside Hospital, Omaha6 trials

Counts are recruiting studies listing at least one site in Nebraska, from ClinicalTrials.gov, refreshed every two days.

Breast Cancer clinical trials in Nebraska: common questions

How many Breast Cancer clinical trials are recruiting in Nebraska?
TrialFinder currently lists 43 recruiting Breast Cancer clinical trials with study sites in Nebraska. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Breast Cancer clinical trials located in Nebraska?
Study sites for the Breast Cancer trials listed on this page include Omaha, Grand Island. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Breast Cancer clinical trial in Nebraska?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Breast Cancer trials in Nebraska also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Breast Cancer clinical trial in Nebraska?
Each study sets its own criteria based on age, Breast Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Do I need to know my receptor status to join a breast cancer trial?
It helps, because trials are organized by subtype, but the study site reads it from your pathology report. If a trial needs a test you have not had, such as HER2-low or a BRCA result, the site arranges it.
Are there trials for early-stage breast cancer?
Yes. Early-stage trials enroll before surgery, after surgery, or during the years of hormone therapy that follow, and test ways to lower the chance the cancer returns. The listing says which window it enrolls in.
Will a trial replace the treatment my oncologist planned?
Sometimes it is the plan, with a new drug added or compared; sometimes it is an alternative to discuss. Bring the trial page to your oncologist, who can refer you to the site or advise on timing.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Breast Cancer trials near you in Nebraska.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Breast Cancer trials →